The Lancet publishes successful study of nebivolol + valsartan in Hypertension - Forest Labs

In a randomised multicentre study in The Lancet, Thomas Giles and colleagues assessed the efficacy and safety of a fixed-dose combination of nebivolol and valsartan from Forest Laboratories in adults with Hypertension. The study's originality is in the components of the combination: a vasodilating beta blocker (nebivolol) and an angiotensin II receptor blocker (valsartan). The trial included 4161 patients with stage 1 or 2 hypertension who were randomly assigned to receive, after completion of a 6-week single-blind placebo run-in phase, double-blind treatment with nebivolol (5 mg/day or 20 mg/day) or valsartan (80 mg/day or 160 mg/day) monotherapies, fixed-dose combinations of nebivolol and valsartan (5 and 80 mg/day, 5 and 160 mg/day, or 10 and 160 mg/day), or placebo.

See- "-Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study"-Prof Thomas D Giles MD, Prof Michael A Weber MD, Prof Jan Basile MD, Prof Alan H Gradman MD, David B Bharucha MD, Wei Chen PhD and others.-May 31, 2014-The Lancet, -Vol. 383 No. 9932 pp 1889-1898.